ARTICLE | Clinical News
Veletri regulatory update
February 25, 2013 8:00 AM UTC
Actelion said Japan's Ministry of Health, Labor and Welfare (MHLW) approved a second-generation formulation of 0.5 and 1.5 mg epoprostenol as Epoprostenol "ACT" to treat pulmonary arterial hypertensio...